News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

Researchers at Cyprus Institute of Neurology & Genetics Complete Third Milestone of CMT1A Gene Therapy Project

Aug 30, 2021 | CMT Research Updates, CMTRF Funded Research, News

The CMT Research Foundation is pleased to announce that Dr. Kleopas A. Kleopa and his team at the Cyprus Institute of Neurology & Genetics, Nicosia, have completed the third milestone of their 24-month CMT1A gene therapy project. CMT1A is caused by duplication of...

DTx Pharma, Inc. Completes CMT Research Foundation-Funded Project

Aug 27, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development

The CMT Research Foundation is pleased to announce that DTx Pharma, Inc. (DTx) has successfully completed their CMT Research Foundation-funded RNA-based therapy project. With funding from the CMT Research Foundation, DTx designed and tested a library of novel...

How the CMT Research Foundation Catalyzes Research into CMT

Jul 20, 2021 | CMT Research Updates, CMTRF Funded Research, Life with CMT, News

An Interview with RareCast's Danny Levine Part of our mission at CMT Research Foundation is to raise awareness about the progress we are making in finding a cure for CMT in the medical, scientific, pharma and patient communities. So, I was pleased to be interviewed on...

Boost for CMT Research with a $3 Million MRFF Grant Awarded for Improving the Diagnosis of Rare Neurogenetic Diseases

Jul 18, 2021 | CMT Research Updates, News, Research News

Professor Marina Kennerson who directs the team at the Northcott Neuroscience Laboratory, ANZAC Research Institute in Sydney Australia is one of the lead researchers awarded a $3 million grant from the Medical Research Future Fund (MRFF) Genomics Health Futures...

CEO Susan Ruediger featured on Global Genes podcast. LISTEN HERE

Jul 16, 2021 | News

To read the full transcription click here.

CMT Research Foundation Targets CMT1X in Partnership with University of Illinois Chicago

Jul 8, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development, News, Research News

The CMT Research Foundation is partnering with the University of Illinois Chicago to test a potential therapeutic for CMT1X, the second most common form of CMT, behind only CMT1A in prevalence. CMT is one of the most common inherited neurological disorders, affecting...

CMT Research Foundation partners with Biotechnology Company AcuraStem and CMT Researcher Alessandra Bolino to test new drug in CMT4B1

Jun 27, 2021 | About CMT, CMT Research Updates, CMTRF Funded Research, Drug Development

The CMT Research Foundation is proud to announce our latest project, a partnership between AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, a renowned expert in CMT and the head of the Human Inherited Neuropathies Unit at the...

CMT Research Foundation To Host First Global Research Convention

Jun 15, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development, News, Press Releases, Research News

Several Hundred Charcot-Marie-Tooth* World Leaders Gather to Accelerate Collaboration and Advancements in Research; Pharma Partner DTx to Review Significant Progress in Drug Delivery Gene Therapy Innovator and Pioneer Dr. James M. Wilson to Keynote ATLANTA (June...

Understanding Neurons and the Myelin Sheath in Charcot-Marie-Tooth Disease

May 14, 2021 | About CMT

By Keith Fargo, Ph.D., Chief Scientific Officer, CMT Research Foundation Charcot-Marie-Tooth disease, or CMT, is a disease in which the peripheral nerves that branch out from the brain and spinal cord to other parts of the body, like our hands and feet, don’t work...

Be the Change We Wish to See: Join the Spring CMT Research Challenge

Apr 19, 2021 | Life with CMT

Tired of living with a disease that has no treatments and cures, Chelsea Layton and her fellow CMT Research Foundation volunteer ambassadors created the Spring CMT Research Challenge to rally the CMT community to help speed drug development and answers. Learn more and join the challenge.